Marshall Edwards changes name to MEI Pharma
Marshall Edwards, a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, had decided to change its name to MEI Pharma, and its common stock will begin trading under the new ticker symbol MEIP.
“Over the past two years we have successfully relocated our headquarters to the U.S., acquired a robust intellectual property portfolio, assembled world-class drug development expertise and advanced our two most promising oncology candidates into clinical trials,” said Daniel P. Gold, Ph.D., president and CEO of Marshall Edwards. "Now, with our drug candidates poised for the next phase of clinical development and our company in a position for growth, it is time for a name that reflects our identity and more effectively conveys our purpose.”
The company’s common stock will be assigned a new CUSIP number of 55279B103 in connection with the name change. Outstanding stock certificates will not be affected and will not need to be exchanged.
Upcoming Events
-
23Apr
-
07May
-
14May